MedTech Atlas
Back to medical device regulatory guideAll countries
EuropeENPublic regulatory overview

Ukraine

Market Overview Population: Approximately 37–40 million (postFebruary 2022, actual incountry population fluctuates significantly due to largescale displacement; prewar population w...

Updated: 2026-05-04

You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.

Sign in / register for full country report
Reference approval strategy

FDA / CE / MDSAP / NMPA benefits for this market

These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.

US FDA

510(k) / De Novo / PMAModerate benefit

FDA evidence is useful technical and clinical support, but the local authority still performs an independent review.

Likely benefit
  • Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
  • May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
  • Does not remove local holder, language, labeling, fee, import, or post-market obligations.
View topic

EU CE

MDR / IVDRStrong benefit

CE documentation is highly reusable and may support reference, reliance, or overseas conformity assessment routes.

Likely benefit
  • Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
  • Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
  • Does not replace local registration or local representative responsibilities outside the CE-recognized route.
View topic

MDSAP

Single QMS auditIndirect QMS signal

MDSAP mainly supports ISO 13485/QMS maturity and does not reduce product review directly.

Likely benefit
  • Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
  • Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
  • Does not authorize product sale and does not replace safety, performance, or clinical evidence.
View topic

China NMPA

China registration / filingSupportive evidence

NMPA approval can serve as prior-market evidence and a commercial credibility signal, especially for China-made products.

Likely benefit
  • Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
  • Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
  • Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
View topic

AI Citation Summary

  • Country: Ukraine
  • Product line: Medical devices
  • Regulator / source: Market characteristics: Pre-war medical device market was approximately USD 700–900 million, with high import dependency (~80%). Since the outbreak of full-scale war in February 2022, the market has contracted significantly, but humanitarian aid, military medical needs, and post-war reconstruction are generating new market opportunities. Ukraine is an EU candidate state (formally granted candidacy in June 2022), and the regulatory framework is aligning toward EU MDR. International aid organizations (WHO, UNICEF, USAID, etc.) are active; the proportion of products entering through humanitarian channels is rising.
  • Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
  • Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
  • Key fees: Market characteristics: Pre-war medical device market was approximately USD 700–900 million, with high import dependency (~80%). Since the outbreak of full-scale war in February 2022, the market has contracted significantly, but humanitarian aid, military medical needs, and post-war reconstruction are generating new market opportunities. Ukraine is an EU candidate state (formally granted candidacy in June 2022), and the regulatory framework is aligning toward EU MDR. International aid organizations (WHO, UNICEF, USAID, etc.) are active; the proportion of products entering through humanitarian channels is rising.
  • Local requirement: Ukraine medical-device entry should be separated into Ukrainian conformity assessment and Ministry of Health / State Service channels regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.
  • Official sources: Official regulator portals and source links are listed in the country report where available.
  • Last verified: 2026-05-04
  • Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
  • Preferred citation: MedTech Atlas

Market Overview

  • Population: Approximately 37–40 million (post-February 2022, actual in-country population fluctuates significantly due to large-scale displacement; pre-war population was approximately 44 million)
  • Healthcare system: The National Health Service of Ukraine (NHS Ukraine / НСЗУ, Національна служба здоров'я України) is the core, with public healthcare reform (Medreform) underway since 2018. Public hospitals dominate; private medical services are growing. Medical resources are unevenly distributed between the east and west; significant healthcare infrastructure has been damaged during the war.
  • Market characteristics: Pre-war medical device market was approximately USD 700–900 million, with high import dependency (~80%). Since the outbreak of full-scale war in February 2022, the market has contracted significantly, but humanitarian aid, military medical needs, and post-war reconstruction are generating new market opportunities. Ukraine is an EU candidate state (formally granted candidacy in June 2022), and the regulatory framework is aligning toward EU MDR. International aid organizations (WHO, UNICEF, USAID, etc.) are active; the proportion of products entering through humanitarian channels is rising.
  • Regulatory maturity: Medium-low. The regulatory framework has historically been influenced by the Soviet GOST system and has been moving toward EU MDR alignment in recent years. Enforcement capacity has been somewhat reduced during the war, but the basic regulatory framework remains operational. EU candidate status will drive deep restructuring of the regulatory system over the medium term.

Market-Entry Logic

Ukraine medical-device entry should be separated into Ukrainian conformity assessment and Ministry of Health / State Service channels regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.

Entry layer Key question Practical view
Regulatory route Which product category, risk class, application type, reliance route, or special pathway applies? Confirm the pathway before translating the dossier; route choice drives evidence, timing, fees, inspections, labelling, and change-control obligations
Local execution Who holds the registration, imports, answers regulator questions, manages safety reporting, and controls renewals or variations? Contract structure matters because local agents, sponsors, distributors, or licence holders can control practical market access even when the foreign manufacturer owns the product
Evidence and economics What clinical, quality, performance, HTA, pricing, and budget-impact evidence is needed? Registration evidence and payer evidence should be planned together; otherwise approval may be achieved without reimbursement, tender access, or hospital adoption
Channel access Which payer, hospital, distributor, retail, tender, or private-care channel will create volume? Start with the channel that matches product value and service burden; premium products often need reference sites before broad tender or retail expansion

Main Players and Channel Map

Type Representative players Market meaning
Regulator / review Ukrainian conformity assessment and Ministry of Health / State Service channels Determines approval route, technical evidence, inspections, labelling, post-market duties, renewals, and variations
Payment / procurement NHSU, Medical Procurement of Ukraine, donor procurement and private providers Determines reimbursement, tender economics, price ceilings, purchasing lists, and patient affordability
Companies / channels local importers, donor-funded suppliers, public hospitals, diagnostic networks and multinational medtech companies Shows the competitive set, partner universe, distribution power, hospital access points, and local execution benchmarks
End users / buyers Public hospitals, private hospital groups, specialist centers, laboratories, pharmacies, insurers, and regional distributors Determine adoption, tender volume, reference cases, service expectations, and receivables risk
  1. Approval and access are increasingly separate: Technical approval does not guarantee reimbursement, procurement listing, physician adoption, or patient affordability.
  2. Local execution quality is a major differentiator: Strong local regulatory, medical, market-access, distribution, and service teams reduce deficiency, launch, and lifecycle risk.
  3. Evidence expectations are rising: Payers and hospitals increasingly ask for comparative clinical value, real-world evidence, budget impact, and operational service data.
  4. Pricing pressure is structural: war-related supply disruption, humanitarian procurement, EU alignment, local distributor resilience, currency/payment risk and reconstruction-driven demand are reshaping launch sequencing and product economics.
  5. Partner control should be managed early: Contracts should protect dossier access, registration ownership, renewal obligations, safety reporting, inventory, and transition rights.

Regulatory Authorities

  • Competent Authority: Ministry of Health of Ukraine (МОЗ, Міністерство охорони здоров'я України) and its subordinate agency, the State Service of Ukraine on Medicines and Narcotics Control (Держлікслужба / ДКЛП, Державна служба з лікарських засобів та контролю за наркотиками)
  • Official portals:
  • Key regulations:
    • Technical Regulations on Medical Devices (Технічний регламент щодо медичних виробів), Cabinet of Ministers Resolution No. 753 (2013), based on the EU MDD 93/42/EEC framework
    • Technical Regulations on Active Implantable Medical Devices (Cabinet Resolution No. 754, 2013)
    • Technical Regulations on IVD Medical Devices (Cabinet Resolution No. 754, corresponding to EU IVDD)
    • State Registration Procedure for Medical Devices (Ministry of Health order)
    • Note: Certain regulatory implementing rules have been adjusted since 2022; a number of temporary exemption provisions have been issued during the wartime period. Verify the latest applicable texts.

Important context: Ukraine formally became an EU candidate state in June 2022, initiating a long-term process of transitioning the regulatory framework toward EU MDR/IVDR. In the short term (2024–2027), the current national regulations (based on the EU MDD framework) remain the primary applicable rules, but legislation drafts aligning with EU MDR are in progress. Monitor updates from the Ministry of Health and EU–Ukraine coordination mechanisms.

Device Classification

Local Classification Risk Level EU/FDA Equivalent Notes
Клас I / Class I Low risk EU MDD Class I / FDA Class I General devices; some require only notification
Клас IIа / Class IIa Medium-low risk EU MDD Class IIa / FDA Class II Requires Notified/Authorized Body involvement
Клас IIб / Class IIb Medium-high risk EU MDD Class IIb / FDA Class II More rigorous review
Клас III / Class III High risk EU MDD/MDR Class III / FDA Class III Implants, high-risk devices

Classification rules reference EU MDD Annex IX rules (not EU MDR, as the current regulation is based on MDD). Transitioning toward EU MDR classification rules is underway; during the transition, dual-track classification may apply in some cases.

Registration Pathway

During the limited-time free period, sign in or register to view the complete medical device country report.